In recent years, there has been great emphasis placed on the importance of cardio-oncology, with both cardiologists and hematologists highlighting... The post The importance of cardio-oncology: awareness around the ESC 2022 guidelines & the value of building MDTs appeared first on VJHemOnc.

Smoldering multiple myeloma (SMM) and monoclonal gammopathy of undetermined significance (MGUS) are two well-known precursor conditions to multiple myeloma, and the... The post Exploring the possibility of early interception in smoldering myeloma: novel agents, challenges & advances in risk stratification appeared first on VJHemOnc.

Clonal hematopoiesis of indeterminate potential (CHIP) and clonal cytopenia of unknown significance (CCUS) are considered precursor diseases to hematologic malignancies,... The post CHIP & CCUS: knowledge gaps, ongoing trials & recommendations for approaching patients with myeloid precursors appeared first on VJHemOnc.

Monoclonal B-cell lymphocytosis (MBL) is a condition characterized by the presence of an abnormal increase in B lymphocytes in the... The post Monoclonal B-cell lymphocytosis: classification, biology and exploring the possibility of early interception appeared first on VJHemOnc.

The introduction of CAR-T therapy has revolutionized the myeloma treatment landscape, offering a promising therapeutic approach for patients with relapsed/refractory... The post The impact of CAR-T therapy on the myeloma treatment landscape, patient selection for CAR-T & the evolving role of autoSCT appeared first on VJHemOnc.

While there have been advances in the treatment and management of amyloidosis in recent years, diagnosis remains a challenge due... The post Diagnosing amyloidosis, currently available therapies & the importance of cardio-oncology appeared first on VJHemOnc.

Although CAR-T cells have revolutionized the treatment of hematological malignancies, there are several important factors that must be addressed regarding... The post Addressing the importance of lymphodepletion, factors contributing to ICAHT & the cost effectiveness of CAR-T therapy appeared first on VJHemOnc.

The treatment landscape of acute lymphoblastic leukemia (ALL) has transformed with the introduction of novel immunotherapeutic agents, including CAR-T cells... The post Updates with the use of CAR-T therapy in ALL: ongoing challenges, strategies to overcome resistance & future outlooks appeared first on VJHemOnc.

The treatment landscape of acute myeloid leukemia (AML) has transformed in recent years with the introduction of novel targeted agents,... The post Targeted therapy in AML: the growing role of menin inhibitors & clinical trials exploring these agents appeared first on VJHemOnc.

Myelodysplastic syndromes (MDS) are a heterogeneous group of hematologic neoplasms which can be categorized into lower- and higher-risk disease (LR-MDS;... The post Updates in lower- and higher-risk MDS: challenges, novel agents & key clinical trials at ASH 2023 appeared first on VJHemOnc.

In the last decade, the treatment landscape of thalassemia has been transformed with the introduction of novel therapies. With several... The post Key updates in thalassemia at ASH 2023: gene therapies, ongoing trials & the value of precision medicine appeared first on VJHemOnc.

Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is an aggressive and rare hematological malignancy associated with poor prognosis. Several challenges remain... The post Updates, challenges and novel agents being explored in BPDCN appeared first on VJHemOnc.

The treatment and management of patients with multiple myeloma is continually evolving, giving rise to novel prognostic tools and therapeutic... The post Unanswered questions regarding the sequencing of BCMA therapies, the prognostic value of CTCs & the growing role of quadruplets appeared first on VJHemOnc.

In recent years, the treatment landscape of sickle cell disease (SCD) has been revolutionized with the introduction of novel agents,... The post Key updates in sickle cell disease at ASH 2023: disease biology, ongoing trials & the growing role of gene therapy appeared first on VJHemOnc.

In recent years, the treatment and management of light chain (AL) amyloidosis has transformed with the introduction of novel agents.... The post ASH 2023 highlights: updates in the diagnosis and treatment of amyloidosis appeared first on VJHemOnc.

The treatment of the BCR-ABL1-negative myeloproliferative neoplasms (MPNs), including myelofibrosis (MF), polycythemia vera (PV) and essential thrombocythemia (ET), has transformed... The post MPN highlights at ASH 2023: novel agents & ongoing clinical trials in ET, PV and MF appeared first on VJHemOnc.

The 20th International Workshop on Non-Hodgkin Lymphoma (iwNHL 2023) took place in Miami, FL, and brought together leading experts as... The post iwNHL 2023 Session V: Expanding the CAR platform in NHL appeared first on VJHemOnc.

The biennial International Workshop on Chronic Lymphocytic LeukemiaTM (iwCLL 2023) was held recently in Boston, MA, and brought together experts who... The post iwCLL 2023: The role of continuous BTKis, approaching Richter’s transformation & addressing the underrepresentation of elderly patients in trials appeared first on VJHemOnc.

The 20th International Workshop on Non-Hodgkin Lymphoma (iwNHL 2023) took place in Miami, FL, and brought together leading experts as... The post iwNHL 2023 Session IV: Novel therapies in NHL: BTK inhibitors, BTK degraders, and bispecific antibodies appeared first on VJHemOnc.

In recent years, there have been promising therapeutic advances in light chain (AL) amyloidosis, however, several unmet needs remain in... The post Unmet needs in AL amyloidosis, novel treatment strategies being explored, and the role of CHIP appeared first on VJHemOnc.